iX Biopharma rights issue closes 196.2% subscribed
42C : 42C 0%'s rights issue closed on July 19 with valid acceptances and valid excess applications amounting to 196.2 per cent of the shares available for subscription, the speciality pharmaceutical company said in a bourse filing on Monday.
Some 48.8 million ordinary shares will be issued at an issue price of S$0.20 per share, to raise net proceeds of S$9.56 million.
The issue price represents a discount of 18.4 per cent to the counter's closing price of 24.5 Singapore cents on June 8, which was the shares' last trading day on the Singapore Exchange (SGX) prior to the announcement of the rights issue.
Net proceeds will be used to fund manufacturing and marketing activities for the group's products and for general working capital purposes, the group said.
iX Biopharma expects the new shares will be listed and quoted on the SGX Catalist board on or around July 28.
Shares of iX Biopharma closed at S$0.23 on Friday, down S$0.01 or 4.2 per cent.
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Under Armour forecasts downbeat annual sales and profit, shares slump
J&J to acquire Proteologix for US$850 million
Watches of Switzerland sees used watch sales double
Consumer groups accuse Temu of manipulating online shoppers
OUE Healthcare proposes sale of mixed commercial site for RM125 million
Fashion brand Esprit files for bankruptcy for its European business